CAD 1.1
(-2.65%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 423 Thousand CAD | 13.4% |
2022 | 373 Thousand CAD | -43.03% |
2021 | 654.75 Thousand CAD | 62.85% |
2020 | 402.05 Thousand CAD | -20.58% |
2019 | 506.27 Thousand CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | -100.0% |
2006 | 150 Thousand CAD | 0.0% |
2005 | 150 Thousand CAD | 0.0% |
2004 | 150 Thousand CAD | 0.0% |
2003 | 150 Thousand CAD | 0.0% |
2002 | 150 Thousand CAD | 0.0% |
2001 | 150 Thousand CAD | 0.0% |
2000 | 150 Thousand CAD | 0.0% |
1999 | 150 Thousand CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 1.12 Million CAD | 166.43% |
2024 Q2 | 1.11 Million CAD | -0.98% |
2023 Q1 | 567 Thousand CAD | 52.01% |
2023 FY | 423 Thousand CAD | 13.4% |
2023 Q4 | 423 Thousand CAD | -17.7% |
2023 Q3 | 514 Thousand CAD | 7.31% |
2023 Q2 | 479 Thousand CAD | -15.52% |
2022 Q4 | 373 Thousand CAD | -19.05% |
2022 Q1 | 584.12 Thousand CAD | -10.79% |
2022 Q2 | 522.44 Thousand CAD | -10.56% |
2022 FY | 373 Thousand CAD | -43.03% |
2022 Q3 | 460.78 Thousand CAD | -11.8% |
2021 Q1 | 624.33 Thousand CAD | 55.28% |
2021 Q2 | 744.5 Thousand CAD | 19.25% |
2021 Q3 | 710.74 Thousand CAD | -4.54% |
2021 Q4 | 654.75 Thousand CAD | -7.88% |
2021 FY | 654.75 Thousand CAD | 62.85% |
2020 FY | 402.05 Thousand CAD | -20.58% |
2020 Q4 | 402.05 Thousand CAD | -22.16% |
2020 Q2 | 325.17 Thousand CAD | -25.63% |
2020 Q3 | 516.51 Thousand CAD | 58.84% |
2020 Q1 | 437.21 Thousand CAD | -13.64% |
2019 Q1 | 778.94 Thousand CAD | 0.0% |
2019 Q3 | 604.13 Thousand CAD | -12.41% |
2019 Q4 | 506.27 Thousand CAD | -16.2% |
2019 FY | 506.27 Thousand CAD | 0.0% |
2019 Q2 | 689.75 Thousand CAD | -11.45% |
2018 Q1 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 FY | - CAD | -100.0% |
2007 Q1 | - CAD | -100.0% |
2007 Q4 | - CAD | 0.0% |
2006 Q2 | 150 Thousand CAD | 0.0% |
2006 FY | 150 Thousand CAD | 0.0% |
2006 Q4 | 150 Thousand CAD | 0.0% |
2006 Q3 | 150 Thousand CAD | 0.0% |
2006 Q1 | 150 Thousand CAD | 0.0% |
2005 Q1 | 150 Thousand CAD | 0.0% |
2005 Q3 | 174.21 Thousand CAD | 16.14% |
2005 Q2 | 150 Thousand CAD | 0.0% |
2005 Q4 | 150 Thousand CAD | -13.9% |
2005 FY | 150 Thousand CAD | 0.0% |
2004 Q1 | 150 Thousand CAD | 0.0% |
2004 Q2 | 150 Thousand CAD | 0.0% |
2004 Q3 | 150 Thousand CAD | 0.0% |
2004 Q4 | 150 Thousand CAD | 0.0% |
2004 FY | 150 Thousand CAD | 0.0% |
2003 Q1 | 150 Thousand CAD | 0.0% |
2003 Q2 | 150 Thousand CAD | 0.0% |
2003 Q3 | 150 Thousand CAD | 0.0% |
2003 Q4 | 150 Thousand CAD | 0.0% |
2003 FY | 150 Thousand CAD | 0.0% |
2002 Q1 | 150 Thousand CAD | 0.0% |
2002 Q3 | 161.9 Thousand CAD | 7.94% |
2002 Q4 | 150 Thousand CAD | -7.35% |
2002 FY | 150 Thousand CAD | 0.0% |
2002 Q2 | 150 Thousand CAD | 0.0% |
2001 FY | 150 Thousand CAD | 0.0% |
2001 Q1 | - CAD | -100.0% |
2001 Q4 | 150 Thousand CAD | 0.0% |
2001 Q2 | 150 Thousand CAD | 0.0% |
2001 Q3 | 150 Thousand CAD | 0.0% |
2000 Q4 | 150 Thousand CAD | 0.0% |
2000 Q2 | 150 Thousand CAD | 0.0% |
2000 FY | 150 Thousand CAD | 0.0% |
2000 Q1 | 150 Thousand CAD | 0.0% |
2000 Q3 | 150 Thousand CAD | 0.0% |
1999 FY | 150 Thousand CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 8.18 Million CAD | 94.832% |
Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 96.931% |
Helix BioPharma Corp. | - CAD | -Infinity% |
Microbix Biosystems Inc. | 6.64 Million CAD | 93.635% |
Medicenna Therapeutics Corp. | - CAD | -Infinity% |
Satellos Bioscience Inc. | - CAD | -Infinity% |
Sernova Corp. | 136.12 Thousand CAD | -210.748% |